Glucosamine and Alzheimer's Disease: What a Landmark Nature Metabolism Study Means for Your Patients Right Now
NEUROLOGY UPDATE | ALZHEIMER'S DISEASE & DEMENTIA CARE June 2026 | NP Chronicles Clinical Education Glucosamine and Alzheimer's Disease: What a Landmark Nature Metabolism Study Means for Your Patients Right Now By Valerie Watters-Burke, DNSc, MSN, MBA, FNP-BC, GNP-BC, PPCNP-BC Based on: Hawkinson TR, Liu Z, et al. Hyperglycosylation is a metabolic driver of Alzheimer's disease. Nature Metabolism. 2026. doi:10.1038/s42255-026-01538-4 CLINICAL BOTTOM LINE ⚠ CLINICAL SAFETY ALERT: A major study published in Nature Metabolism (June 2026) found that glucosamine supplementation — one of the most widely used OTC joint health supplements — is associated with a 25% increase in mortality in patients with Alzheimer's disease-related dementia (ADRD), and a 25% increase in MCI-to-AD conversion rates. The biological mechanism is now well-characterized: glucosamine feeds the hexosamine biosynthetic pathway, driving brain hy...